GlassScriptPhysician profile
Manuel T Peralta
NPI 1245451194
$14,863.04
in general payments reported to CMS, 2019-2025
52 companies · $2,399 in 2025
The $2,399 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,263 · 2020: $1,065 · 2021: $2,758 · 2022: $2,235 · 2023: $2,663 · 2024: $2,481 · 2025: $2,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,497 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,497.33 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,087.53 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,639.60 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,361.87 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $1,308.06 | 2019-2025 | |
| Amgen INC. | $1,004.04 | 2019-2025 | Evenity, Prolia, Repatha |
| Abbott Laboratories | $756.84 | 2019-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $673.68 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $621.96 | 2019-2025 | Spravato, Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.84 | 2019-2025 | Jardiance, Synjardy |
| Astellas Pharma US INC | $445.27 | 2019-2025 | Veozah, Myrbetriq |
| Glaxosmithkline, LLC. | $393.97 | 2019-2025 | Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $342.97 | 2019-2025 | Xifaxan, Trulance |
| Dexcom, INC. | $302.66 | 2021-2025 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $265.83 | 2021 | |
| Esperion Therapeutics, INC. | $233.63 | 2020-2025 | Nexletol |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manuel Peralta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.